Hyderabad, Telangana, India, March 2025 – Neuland Laboratories Limited has announced the appointment of Parag Deshmukh as Senior Vice President – Head of Manufacturing, effective March 10, 2025. In this role, he will lead manufacturing operations across Neuland’s facilities, driving efficiency, compliance, and operational excellence while supporting the company’s strategic growth initiatives in API manufacturing. With over 23 years of industry experience, including more than 21 years in the pharmaceutical API sector, he brings a wealth of expertise in shop floor operations, cost management, ESG initiatives, and senior leadership in pharmaceutical manufacturing.
Before joining Neuland Laboratories, Parag served as Senior Director at Cipla for nearly four years, where he was responsible for enhancing operational efficiencies and optimizing manufacturing processes at the company’s API facilities. His leadership contributed to driving sustainability measures, process improvements, and workforce development strategies.
Prior to Cipla, he was Associate Vice President – Operations at Aurobindo Pharma Limited, where he led manufacturing and operational strategies, ensuring compliance with regulatory standards and enhancing production efficiencies. His role involved implementing best practices in API production, scaling up manufacturing capabilities, and driving quality improvements.
Parag spent nearly two decades at Lupin Limited, holding leadership positions, including General Manager of Operations. During his 19-year tenure, he played a key role in expanding API production capabilities, implementing cost optimization strategies, and strengthening quality assurance practices. His extensive experience in process engineering, operational leadership, and large-scale manufacturing execution makes him an asset to Neuland Laboratories’ manufacturing ecosystem.
About Neuland Laboratories
Neuland Laboratories Limited is a leading manufacturer of active pharmaceutical ingredients (APIs) and an end-to-end solutions provider for the pharmaceutical industry. With three FDA-inspected facilities, over 1,000 employees, and customers across 85+ countries, Neuland specializes in contract research, contract manufacturing, and generic API production. The company remains committed to delivering superior quality products and driving innovation in complex chemistry.
Read Also : Entering 2025, TA Leaders’ Success Built on More than Just Hiring, Says The Josh Bersin Company
People Analytics Teams Still Struggle to Deliver Business Impact, Warns The Josh Bersin Company
ESG and Women’s Leadership: Driving Sustainability and Inclusion
Learning and Development Trends for 2025: Shaping the Future of Workplace Learning
